The Development and Evaluation of Pan-Coronavirus Vaccines

泛冠状病毒疫苗的研发与评价

基本信息

  • 批准号:
    10420511
  • 负责人:
  • 金额:
    $ 799.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-02 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

Overall Summary Given the historical outbreaks of coronaviruses, coupled with the recent emergence of SARS- CoV-2 and the destabilizing consequence of COVID-19 on global health and economy, there is an urgent and critical need to develop new vaccines capable of broad protection against existing and future Sarbecoviruses and Merbecoviruses. This P01 program project (PPG) addresses the hypothesis that a combination of evolutionarily-designed and optimized B and T cell antigens can confer broad and protective immunity against Sarbecoviruses and Merbecoviruses that currently exist or could emerge from zoonotic reservoirs. The PPG integrates the work of eleven leading laboratories with records of collaboration that have expertise in coronavirus biology, viral pathogenesis, B and T cell immunity, vaccine development, animal challenge studies, structural biology, antibody structure and function, antigen design, and evolutionary analysis of viruses. All Projects and Cores plan interactive studies with the focused goal of designing optimized B and T cell antigens for incorporation in adenoviral (ChAd) and vesicular stomatitis virus (VSV) vectors to create mucosal and systemic vaccines that protect against infection and disease caused by a range of coronaviruses of potential concern. The PPG is served by a central Animal Challenge Core that performs vaccination and infection experiments in mice and hamsters and a central Administrative Core that streamlines data management and sharing, provides computational analysis for down-selection and scientific decision-making, and facilitates communication. Our proposal and antigen design program serves as a blueprint for possible product development with ChAd vaccines, VSV-based vaccines, or even with other platforms (e.g., mRNA vaccines, nanoparticles, etc.) not directly evaluated here. By the conclusion of our PPG, we envision generating at least one and likely multiple viral- vectored vaccine platforms that induce broad spectrum immunity to multiple coronaviruses of concern including human and zoonotic Sarbecoviruses and Merbecoviruses that could emerge in the future.
整体总结

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael S Diamond其他文献

West Nile virus: crossing the blood-brain barrier
西尼罗河病毒:穿越血脑屏障
  • DOI:
    10.1038/nm1204-1294
  • 发表时间:
    2004-12-01
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Michael S Diamond;Robyn S Klein
  • 通讯作者:
    Robyn S Klein
MDA5 and autoimmune disease
MDA5 与自身免疫性疾病
  • DOI:
    10.1038/ng.2959
  • 发表时间:
    2014-04-28
  • 期刊:
  • 影响因子:
    29.000
  • 作者:
    Jonathan J Miner;Michael S Diamond
  • 通讯作者:
    Michael S Diamond
Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development
寨卡病毒疫苗和单克隆抗体:研发的优先议程
  • DOI:
    10.1016/s1473-3099(24)00750-3
  • 发表时间:
    2025-07-01
  • 期刊:
  • 影响因子:
    31.000
  • 作者:
    Julia T Ostrowsky;Leah C Katzelnick;Nigel Bourne;Alan D T Barrett;Stephen J Thomas;Michael S Diamond;David W C Beasley;Eva Harris;Annelies Wilder-Smith;Tabitha Leighton;Angela J Mehr;Nicolina M Moua;Angela K Ulrich;Ana Cehovin;Petra C Fay;Josephine P Golding;Kristine A Moore;Michael T Osterholm;Eve M Lackritz;Kristina M Adams Waldorf;Jurai Wongsawat
  • 通讯作者:
    Jurai Wongsawat

Michael S Diamond的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael S Diamond', 18)}}的其他基金

Development of Viral Vaccines against Sarbecoviruses and Merbecoviruses
Sarbecoviruses和Merbecoviruses病毒疫苗的研制
  • 批准号:
    10420516
  • 财政年份:
    2022
  • 资助金额:
    $ 799.08万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10420512
  • 财政年份:
    2022
  • 资助金额:
    $ 799.08万
  • 项目类别:
LDLRAD3 Receptor Interaction with Venezuelan Equine Encephalitis Virus
LDLRAD3 受体与委内瑞拉马脑炎病毒的相互作用
  • 批准号:
    10435558
  • 财政年份:
    2021
  • 资助金额:
    $ 799.08万
  • 项目类别:
Gut Microbiota Modulation of Chikungunya Virus Infection and Pathogenesis
基孔肯雅病毒感染和发病机制的肠道微生物群调节
  • 批准号:
    10379327
  • 财政年份:
    2021
  • 资助金额:
    $ 799.08万
  • 项目类别:
LDLRAD3 Receptor Interaction with Venezuelan Equine Encephalitis Virus
LDLRAD3 受体与委内瑞拉马脑炎病毒的相互作用
  • 批准号:
    10314344
  • 财政年份:
    2021
  • 资助金额:
    $ 799.08万
  • 项目类别:
Gut Microbiota Modulation of Chikungunya Virus Infection and Pathogenesis
基孔肯雅病毒感染和发病机制的肠道微生物群调节
  • 批准号:
    10597063
  • 财政年份:
    2021
  • 资助金额:
    $ 799.08万
  • 项目类别:
LDLRAD3 Receptor Interaction with Venezuelan Equine Encephalitis Virus
LDLRAD3 受体与委内瑞拉马脑炎病毒的相互作用
  • 批准号:
    10661719
  • 财政年份:
    2021
  • 资助金额:
    $ 799.08万
  • 项目类别:
Systemic Neurotropic virus infection effects on GI Dysmotility
全身嗜神经病毒感染对胃肠道运动障碍的影响
  • 批准号:
    10190929
  • 财政年份:
    2020
  • 资助金额:
    $ 799.08万
  • 项目类别:
Systemic Neurotropic virus infection effects on GI Dysmotility
全身嗜神经病毒感染对胃肠道运动障碍的影响
  • 批准号:
    10611909
  • 财政年份:
    2020
  • 资助金额:
    $ 799.08万
  • 项目类别:
Systemic Neurotropic virus infection effects on GI Dysmotility
全身嗜神经病毒感染对胃肠道运动障碍的影响
  • 批准号:
    10396586
  • 财政年份:
    2020
  • 资助金额:
    $ 799.08万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 799.08万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 799.08万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 799.08万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 799.08万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 799.08万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 799.08万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 799.08万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 799.08万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 799.08万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 799.08万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了